• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Published Third Party, Independent Research Corroborates Promise of TAP Cancer Therapeutic As a Therapy for the Treatment of Cancer

Posted on: Monday, 2 June 2008, 09:19 CDT

TapImmune Inc. (OTCBB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced that an independent third party research article in the Journal of Investigative Dermatology has confirmed and corroborated that a TAP incorporated vaccine should be considered as a therapy for the treatment of cancer, in this case, Melanoma.

The article, in advance online publication 3 April 2008, titled, "Restoration of the Expression of Transporters Associated with Antigen Processing in Human Malignant Melanoma Increases Tumor-Specific Immunity," is yet another promising research study that confirms and corroborates the TAP incorporated vaccine. There is now a vast amount of research data supporting and corroborating the initial description of the promising effect of TAP as a cancer therapy and their effect on tumor recognition.

TapImmune patented this novel cancer treatment in 2002 and has been developing it for clinical evaluation. This year it is our intention to bring all this work and research forward by initiating our first cGMP vaccine manufacturing contract. This will enable us to initiate toxicology testing and begin protocol design for a First-In-Man trial (phase 1). Updates are available on our website, so please visit www.tapimmune.com and sign up for additional news alerts.

To read the full article referenced in this release please visit http://www.nature.com/jid/journal/vaop/ncurrent/full/jid200810a.html

About TapImmune

TapImmune is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company's lead product, TAP vaccine, performs a key step in moving characteristic markers called antigens to the surfaces of cells. TAP, or Transporters Associated with Antigen Processing, are proteins responsible for supplying tumor-associated antigens (markers) and viral antigens to the surface of infected cells. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected.

The Company's vaccine has shown, in preclinical tests, effective restoration of TAP which restores and augments the marker (antigen) presentation and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works as an adjuvant or 'accelerant' to enhance targeted vaccines against infectious diseases. The global vaccine market is expected to grow from $13 billion in 2007 to $21 billion in 2010.

TapImmune is preparing GLP manufactured materials for the commencement of toxicology studies on the AdhTAP vaccine, leading to the initiation of a Phase I clinical trial. The Company is also developing a TAP-based vaccine adjuvant which existing preclinical data suggest increases the efficacy of targeted prophylactic vaccines by up to 1000 times.

Additional information on the Company can be found on its web site www.TapImmune.com

Safe Harbor Statement

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-KSB and other SEC filings which are available through EDGAR at www.sec.gov. These are among the primary risks we foresee at the present time. The Company assumes no obligation to update the forward-looking statements.

 Contact for this Press Release: Denis Corin TapImmune Inc. 604 264 8274  

SOURCE: TapImmune Inc.

Source: MARKET WIRE

More News in this Category